Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 140

1.

Six months of parathyroid Hormone (1-84) administered concurrently versus sequentially with monthly ibandronate over two years: the PTH and ibandronate combination study (PICS) randomized trial.

Schafer AL, Sellmeyer DE, Palermo L, Hietpas J, Eastell R, Shoback DM, Black DM.

J Clin Endocrinol Metab. 2012 Oct;97(10):3522-9. doi: 10.1210/jc.2012-1844. Epub 2012 Jul 12.

2.

Randomized trial of once-weekly parathyroid hormone (1-84) on bone mineral density and remodeling.

Black DM, Bouxsein ML, Palermo L, McGowan JA, Newitt DC, Rosen E, Majumdar S, Rosen CJ; PTH Once-Weekly Research (POWR) Group..

J Clin Endocrinol Metab. 2008 Jun;93(6):2166-72. doi: 10.1210/jc.2007-2781. Epub 2008 Mar 18.

3.

Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.

Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM.

J Clin Endocrinol Metab. 2006 Apr;91(4):1370-5. Epub 2006 Jan 31.

PMID:
16449339
4.

Postmenopausal women treated with combination parathyroid hormone (1-84) and ibandronate demonstrate different microstructural changes at the radius vs. tibia: the PTH and Ibandronate Combination Study (PICS).

Schafer AL, Burghardt AJ, Sellmeyer DE, Palermo L, Shoback DM, Majumdar S, Black DM.

Osteoporos Int. 2013 Oct;24(10):2591-601. doi: 10.1007/s00198-013-2349-y. Epub 2013 Apr 16.

PMID:
23589163
5.

Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.

Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.

J Bone Miner Res. 2011 Mar;26(3):503-11. doi: 10.1002/jbmr.238.

6.

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.

Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.

Clin Ther. 2009 Apr;31(4):751-61. doi: 10.1016/j.clinthera.2009.04.018.

PMID:
19446148
7.

Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis.

Lewiecki EM, Keaveny TM, Kopperdahl DL, Genant HK, Engelke K, Fuerst T, Kivitz A, Davies RY, Fitzpatrick LA.

J Clin Endocrinol Metab. 2009 Jan;94(1):171-80. doi: 10.1210/jc.2008-1807. Epub 2008 Oct 7.

PMID:
18840641
8.

Efficacy and safety of monthly ibandronate in men with low bone density.

Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.

Bone. 2010 Apr;46(4):970-6. doi: 10.1016/j.bone.2009.12.034. Epub 2010 Jan 6.

PMID:
20060082
9.
10.

Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis.

Black DM, Bilezikian JP, Greenspan SL, Wüster C, Muñoz-Torres M, Bone HG, Rosen CJ, Andersen HS, Hanley DA.

Osteoporos Int. 2013 Apr;24(4):1503-11. doi: 10.1007/s00198-012-2098-3. Epub 2012 Aug 29.

11.
12.

Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study.

Delmas PD, Adami S, Strugala C, Stakkestad JA, Reginster JY, Felsenberg D, Christiansen C, Civitelli R, Drezner MK, Recker RR, Bolognese M, Hughes C, Masanauskaite D, Ward P, Sambrook P, Reid DM.

Arthritis Rheum. 2006 Jun;54(6):1838-46.

13.

Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study.

Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR.

J Rheumatol. 2008 Mar;35(3):488-97. Epub 2008 Feb 1.

PMID:
18260172
14.

Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension.

Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D.

Osteoporos Int. 2012 Jun;23(6):1769-78. doi: 10.1007/s00198-011-1793-9.

PMID:
21975558
15.

Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long-term extension.

Stakkestad JA, Lakatos P, Lorenc R, Sedarati F, Neate C, Reginster JY.

Clin Rheumatol. 2008 Aug;27(8):955-60. doi: 10.1007/s10067-007-0824-6. Epub 2008 Jan 8.

PMID:
18180976
16.

Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.

McClung MR, Wasnich RD, Recker R, Cauley JA, Chesnut CH 3rd, Ensrud KE, Burdeska A, Mills T; Oral Ibandronate Study Group..

J Bone Miner Res. 2004 Jan;19(1):11-8.

17.

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE)..

J Bone Miner Res. 2004 Aug;19(8):1241-9. Epub 2004 Mar 29.

18.
19.

Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.

Li M, Xing XP, Zhang ZL, Liu JL, Zhang ZL, Liu DG, Xia WB, Meng XW.

J Bone Miner Metab. 2010 May;28(3):299-305. doi: 10.1007/s00774-009-0126-y. Epub 2009 Oct 24.

PMID:
19855926
20.

Once-monthly dosing: an effective step forward.

Reid DM.

Bone. 2006 Apr;38(4 Suppl 1):S18-22. Epub 2006 Mar 13. Review.

PMID:
16533625

Supplemental Content

Support Center